N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma

J. Kang, P. G. Rychahou, T. A. Ishola, J. M. Mourot, B. M. Evers, D. H. Chung

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1α expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.

Original languageEnglish (US)
Pages (from-to)3999-4007
Number of pages9
JournalOncogene
Volume27
Issue number28
DOIs
StatePublished - Jun 26 2008
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Neuroblastoma
Vascular Endothelial Growth Factor A
Sirolimus
Small Interfering RNA
Hypoxia-Inducible Factor 1
Somatomedins
Phosphoric Monoester Hydrolases
Adenoviridae
Transfection
Phosphorylation
Messenger RNA
Serum

Keywords

  • Angiogenesis
  • MYCN
  • Neuroblastoma
  • PI3K/Akt
  • VEGF

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Kang, J., Rychahou, P. G., Ishola, T. A., Mourot, J. M., Evers, B. M., & Chung, D. H. (2008). N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene, 27(28), 3999-4007. https://doi.org/10.1038/onc.2008.15

N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. / Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.

In: Oncogene, Vol. 27, No. 28, 26.06.2008, p. 3999-4007.

Research output: Contribution to journalArticle

Kang, J, Rychahou, PG, Ishola, TA, Mourot, JM, Evers, BM & Chung, DH 2008, 'N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma', Oncogene, vol. 27, no. 28, pp. 3999-4007. https://doi.org/10.1038/onc.2008.15
Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene. 2008 Jun 26;27(28):3999-4007. https://doi.org/10.1038/onc.2008.15
Kang, J. ; Rychahou, P. G. ; Ishola, T. A. ; Mourot, J. M. ; Evers, B. M. ; Chung, D. H. / N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. In: Oncogene. 2008 ; Vol. 27, No. 28. pp. 3999-4007.
@article{2ae982e5fbeb48b5b8356d6967b82d1c,
title = "N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma",
abstract = "Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1α expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.",
keywords = "Angiogenesis, MYCN, Neuroblastoma, PI3K/Akt, VEGF",
author = "J. Kang and Rychahou, {P. G.} and Ishola, {T. A.} and Mourot, {J. M.} and Evers, {B. M.} and Chung, {D. H.}",
year = "2008",
month = "6",
day = "26",
doi = "10.1038/onc.2008.15",
language = "English (US)",
volume = "27",
pages = "3999--4007",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "28",

}

TY - JOUR

T1 - N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma

AU - Kang, J.

AU - Rychahou, P. G.

AU - Ishola, T. A.

AU - Mourot, J. M.

AU - Evers, B. M.

AU - Chung, D. H.

PY - 2008/6/26

Y1 - 2008/6/26

N2 - Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1α expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.

AB - Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1α expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.

KW - Angiogenesis

KW - MYCN

KW - Neuroblastoma

KW - PI3K/Akt

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=46249116654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249116654&partnerID=8YFLogxK

U2 - 10.1038/onc.2008.15

DO - 10.1038/onc.2008.15

M3 - Article

C2 - 18278068

AN - SCOPUS:46249116654

VL - 27

SP - 3999

EP - 4007

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 28

ER -